[Funding alert] Cambridge-based Startup, Zetta Genomics Raises Additional £1.8 Million in Seed Funding

Read also - Copenhagen-based Pluto.markets Secures €2.4 Million in Funding

Zetta Genomics founder and CEO, Ignacio Medina, said, “Zetta Genomics is already making a difference to patients as XetaBase empowers clinicians to make faster and more accurate diagnoses at scale. With this extension to our second seed funding round now finalised, we are scaling and innovating our technologies, and enhancing customer focus.”

Zetta Genomics’ latest funding sees fresh commitments from second-round global investors – some of the most innovative and successful healthtech VCs in the world: Nina Capital; Apex Ventures; and Cambridge Enterprise. New investment comes from We Venture – the innovation VC arm of global specialised diagnostics leader, Werfen.

Read also - Vilnius-based Axiology Secures €2 Million in Funding

Louise Warme, head of We Venture Capital said, “Zetta provides an incredibly powerful tool for analysis and WeVenture strengthens Zetta Genomics’ investor expertise with a focus on innovative diagnostic start-ups poised to transform markets. data management in the quickly expanding NGS market. Increased speed and precision in analysis will support both patient outcome as well as workflow for the healthcare system and research. We are very impressed with the Zetta teams´ capacity and very much look forward to our collaboration going forward.”

The latest £1.8 million investment accelerates momentum and builds on Zetta Genomics’ £2.5 million first seed round finalised in February 2022 and £1.9 million in April 2023. Since then, Zetta Genomics has: expanded its footprint with new headquarters in Cambridge UK and offices in Valencia, Spain built out strategic partnerships with industry leaders including Microsoft, Fujitsu and IQVIA.

Read also - Stockholm-based MANTLE Raises over €2.8 Million in Funding

Dr. Elaine Loukes, Investment Director at Cambridge University, said, “Zetta Genomics’ pioneering technologies – spun out from the University of Cambridge – are maturing to the point where they will make medical research more efficient, deliver ever more effective care – and make this care more affordable. Zetta Genomics’ technologies will power improved health outcomes for millions of people around the world.”

About Zetta Genomics

Zetta Genomics is a spin-out of Genomics England and the University of Cambridge, two of the pioneers of genomic data. Their personnel have worked at the forefront, influencing the development of cutting-edge technologies for huge genomic data as well as their use in research and therapeutic settings.

Read also - Stockholm-based Myrspoven Secures €5.4 Million in Funding